RT Journal Article
SR Electronic
T1 A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 5732
OP 5734
DO 10.1158/1078-0432.CCR-19-1799
VO 25
IS 19
A1 Su, Tina Tianjiao
A1 Gao, Xiaobin
A1 Wang, Jun
YR 2019
UL http://clincancerres.aacrjournals.org/content/25/19/5732.abstract
AB 4-1BB (CD137) is an important costimulatory molecule upregulated on antigen-experienced T cells, however, clinical development of 4-1BB agonists has stalled because of significant liver immuno-toxicity. Using rational protein engineering, a next-generation anticalin-antibody–based therapy achieved localized 4-1BB activation triggered by tumor-expressed antigen, helping to revitalize this pathway in immuno-oncology.See related article by Hinner et al., p. 5878